ArticleResearch in autism2026
Congenital Muscular Torticollis as a Potential Neonatal Marker of Autism Spectrum Disorder and Other Neurodevelopmental Conditions.
Article in Research in autism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Health databases and early identification of autism spectrum disorder: a scoping review.BMJ open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Early intervention consistently improves developmental outcomes in children with autism spectrum disorder (ASD) and related conditions, underscoring the importance for timely recognition. Identifying early markers of atypical neurodevelopment is therefore critical. Congenital muscular torticollis (CMT), unilateral shortening of the sternocleidomastoid muscle causing infant head tilt, shares prenatal and perinatal risk factors with ASD and other developmental abnormalities. This overlap suggests that CMT may signal early disruption in neural development, potentially enabling earlier surveillance and intervention. However, large-scale evidence is scarce. Methods: We used electronic records (live births 2005-2018; follow-up through 2024) from a large Israeli Health Maintenance Organization (HMO) to match 14,150 infants diagnosed with CMT by six months of age with unexposed peers. ASD and related conditions were ascertained via validated algorithms. Upper-respiratory and gastroenteritis infections served as negative control outcomes. Early physical therapy was examined as a potential effect modifier. Results: Children with CMT had increased odds of ASD (odds ratio [OR]=1.25, 95% CI: 1.08-1.45) and developmental language disorder (1.25, 1.16-1.34), relative to unexposed peers. These associations persisted after accounting for maternal and perinatal factors, were absent for the negative control outcomes, and were stronger, though less precise, in infants who received physical therapy. Conclusion: CMT is associated with elevated risks for later atypical neurodevelopment. The results suggest a possible etiological link between abnormal neural circuit maturation and musculoskeletal development. Although CMT is often considered benign in infancy, it may represent an early clinical marker of neurodevelopmental vulnerability, highlighting an opportunity for earlier recognition and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.